Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor
Details : IMC-001 is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 15, 2024
ImmuneOncia Announces Phase 2 Results of PD-L1 Immune Checkpoint Inhibitor at ESMO Asia
Details : IMC-001 is a PD-L1 antibody, an immune checkpoint inhibitor. This antibody activates the anticancer functions of T cells by strongly inhibiting the binding between PD-1 expressed on T cells and PD-L1 expressed on the surface of cancer cells.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
December 05, 2022
A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy
Details : IMC-002 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 11, 2022
Lead Product(s) : IMC-002
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : 3D Medicines Corporation
Deal Size : $470.0 million
Deal Type : Collaboration
Details : The agreement includes uses of IMC-002 for oncology indication as a monotherapy or combination agent in the Territory of Greater China (Mainland China, Hong Kong, Macau, and Taiwan).
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : $8.0 million
March 31, 2021
Lead Product(s) : IMC-002
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : 3D Medicines Corporation
Deal Size : $470.0 million
Deal Type : Collaboration
Lead Product(s) : IMC-002
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Samsung Biologics
Deal Size : Undisclosed
Deal Type : Agreement
Samsung Biologics, ImmuneOncia Enter Into Manufacturing Development Agreement
Details : Samsung Biologics will provide a full scope of CDO services from cell line development, process development, non-clinical and clinical material manufacturing, to IND submission support for global clinical trials of five candidates from ImmuneOncia's pipe...
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
July 16, 2020
Lead Product(s) : IMC-002
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Samsung Biologics
Deal Size : Undisclosed
Deal Type : Agreement
A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type
Details : IMC-001 is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma, Extranodal NK-T-Cell.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 04, 2020
Details : IMC-002 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 12, 2020
Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors
Details : IMC-001 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 23, 2018
Reset All
